[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-335757-en":59,"doc-seo-335757-105":79},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":72,"language_code":73,"site_id":74,"html_lang":73,"table_of_contents":75,"faqs":76,"seo_title":77,"seo_description":66,"update_tm":78,"read_time":31,"preview_page_count":4},335757,687197207919,"Theodora","https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinoma","Fibrolamellar hepatocellular carcinoma (FLC) is a rare liver cancer defined by the DNAJB1::PRKACA fusion, yet similar tumors with protein kinase A (PKA) alterations have been reported. A massive multi-omics analysis uses transcriptomic profiling of 1412 liver tumors to determine tumor-specific versus shared dysregulations. The resulting FLC transcriptomic signature unifies FLC tumors despite different PKA activation routes and supports spatial single-cell dissection of tumor, normal, stromal, and infiltrating immune cells. Primary tumors and metastases are highly similar, with minimal transcript differences, informing diagnosis, classification, and model validation.","Article [https://doi.org/10.1038/s41467-024-55238-2](https://doi.org/10.1038/s41467-024-55238-2)  \nLiver cancer multiomics reveals diverse protein kinase A disruptions convergently produce ﬁbrolamellar hepatocellular carcinoma  \nReceived: 7 May 2024  \n\n| Accepted: 3 December 2024 |\n| --- |\n| |\n| Check for updates |\n\nDavid Requena 1, Jack A. Medico 1, Luis F. Soto-Ugaldi 1, Mahsa Shirani1, James A. Saltsman III1, Michael S. Torbenson2, Philip Cofﬁno1 &  \nSanford M. Simon 1   \nFibrolamellar Hepatocellular Carcinoma (FLC) is a rare liver cancer characterized by a fusion oncokinase of the genes DNAJB1 and PRKACA, the catalytic subunit of protein kinase A (PKA). A few FLC-like tumors have been reported showing other alterations involving PKA. To better understand FLCpathogenesis and the relationships among FLC, FLC-like, and other liver tumors, we performed a massive multi-omics analysis. RNA-seq data of 1412 liver tumors from FLC, hepatocellular carcinoma, hepatoblastoma and intrahepatic cholangiocarcinoma are analyzed, obtaining transcriptomic signatures unrestricted by experimental processing methods. These signatures reveal which dysregulations are unique to speciﬁc tumors and which are common to all liver cancers. Moreover, the transcriptomic FLC signature identiﬁes a unifying phenotype for all FLC tumors regardless of how PKA was activated. We study this signature at multi-omics and single-cell levels in the ﬁrst spatial transcriptomic characterization of FLC, identifying the contribution of tumor, normal, stromal, and inﬁltrating immune cells. Additionally, we study FLC metastases, ﬁnding small differences from the primary tumors.  \nFibrolamellar Hepatocellular Carcinoma (FLC) is a rare liver cancer1,2 that occurs in patients without a history of viral hepatitis, cirrhosis, or other known risk factors3–5. FLC presents with nonspeciﬁc and vague symptoms2,6–8, and there are no serum biomarkers. The diagnosis of FLC, even from pathology slides, can be problematic9, contributing to misdiagnosis and underdiagnosis10,11. Thus, FLC has frequently metastasized by the time of diagnosis, which is lethal7,12,13. FLC is classiﬁed as a subtype of Hepatocellular Carcinoma (HCC)14. However, the transcriptome and proteome of FLC tumors are distinct from those of adjacent non-transformed (called “normal”) tissue and of HCC15,16. Characterizing the molecular changes occurring in FLC tumors and the different cell types  \nincluded in surgical samples could provide markers for diagnosis, prognosis, and therapeutic interventions10.  \nIn FLC17, a heterozygous deletion of ~ 400 Kb in chromosome 19p13.12 connects exon 1 of DNAJB1 with the exons 2–10 of PRKACA (the catalytic subunit of Protein Kinase A)18,19. Producing this deletion20,21, or just expression of the DNAJB1::PRKACA transcript20, issufﬁcient to create the tumor in mouse liver or human hepatocytes, and elimination of the fusion transcript is sufﬁcient to kill the tumor22,23. No other recurrent mutations have been observed in FLC17. These results demonstrate that FLC is the result of a somatic mutation. It is not genetically inherited, and FLC is both triggered by and driven by the DNAJB1::PRKACA fusion.  \n1Laboratory of Cellular Biophysics, The Rockefeller University, New York, NY, USA. 2Division of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA. e-mail: [simon@rockefeller.edu](simon@rockefeller.edu)  \nThere are numerous unresolved questions: What are the pathways of pathogenesis; what is the relation between primary and metastatic tumors; what are the contributions of DNA methylation; how similar or different is FLC from other liver tumors, especially those considered FLC-like? Interestingly, tumors with FLC-like histopathology have been reported in patients missing expression of PRKAR1A (an inhibitory regulatory subunit of PKA)24, or with alternate fusions between ATP1B1 and a catalytic subunit of PKA25. Moreover, ﬁbrotic tumors with histological features of both HCC and FLC have b","cbCaigyujQu64KKy","https://ap.wps.com/l/cbCaigyujQu64KKy","pdf",30324688,"English","en",105,"# Abstract\n## Background and motivation\n## Multi-omics design and data scope\n## Transcriptomic FLC signature and validation\n## Spatial single-cell characterization\n## Metastasis comparisons\n## Implications and applications","[{\"question\":\"What defines fibrolamellar hepatocellular carcinoma (FLC) in the study?\",\"answer\":\"FLC is characterized by a fusion oncokinase DNAJB1::PRKACA involving the catalytic subunit of protein kinase A (PKA). The study also considers FLC-like tumors with additional PKA-related alterations.\"},{\"question\":\"How was the multi-omics analysis performed?\",\"answer\":\"RNA-seq data from 1412 liver tumors spanning FLC, hepatocellular carcinoma, hepatoblastoma, and intrahepatic cholangiocarcinoma were analyzed, with further integration using multi-omics and single-cell spatial transcriptomics on a spatially resolved characterization of FLC.\"},{\"question\":\"What do the transcriptomic signature results show about FLC and FLC-like tumors?\",\"answer\":\"The transcriptomic FLC signature identifies a unifying phenotype across FLC tumors regardless of how PKA was activated, showing that FLC and FLC-like tumors behave as a single disease with a common transcriptome rather than distinct diseases with similar pathology.\"}]","Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinoma | PDF",1790012215,{"code":4,"msg":80,"data":81},"ok",{"site_id":74,"language":73,"slug":82,"title":65,"keywords":83,"description":66,"schema_data":84,"social_meta":138,"head_meta":140,"extra_data":142,"updated_unix":143},"liver-cancer-multiomics-reveals-diverse-protein-kinase-a-disruptions-convergently-produce-fibrolamellar-hepatocellular-carcinoma","",{"@graph":85,"@context":137},[86,100,120],{"@type":87,"itemListElement":88},"BreadcrumbList",[89,93,95,98],{"item":90,"name":91,"@type":92,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":94,"name":9,"@type":92,"position":14},"https://docshare.wps.com/document/",{"item":96,"name":40,"@type":92,"position":97},"https://docshare.wps.com/document/research-report/",3,{"item":99,"name":65,"@type":92,"position":19},"https://docshare.wps.com/document/liver-cancer-multiomics-reveals-diverse-protein-kinase-a-disruptions-convergently-produce-fibrolamellar-hepatocellular-carcinoma/335757/",{"url":99,"name":65,"@type":101,"image":102,"author":107,"headline":65,"publisher":109,"fileFormat":112,"inLanguage":73,"description":66,"dateModified":113,"datePublished":114,"encodingFormat":112,"isAccessibleForFree":115,"interactionStatistic":116},"DigitalDocument",{"url":103,"@type":104,"width":105,"height":106},"https://docshare.wps.com/thumbnails/liver-cancer-multiomics-reveals-diverse-protein-kinase-a-disruptions-convergently-produce-fibrolamellar-hepatocellular-carcinoma/335757.png","ImageObject",300,407,{"name":63,"@type":108},"Person",{"url":90,"name":110,"@type":111},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":117,"interactionType":118,"userInteractionCount":34},"InteractionCounter",{"@type":119},"ViewAction",{"@type":121,"mainEntity":122},"FAQPage",[123,129,133],{"name":124,"@type":125,"acceptedAnswer":126},"What defines fibrolamellar hepatocellular carcinoma (FLC) in the study?","Question",{"text":127,"@type":128},"FLC is characterized by a fusion oncokinase DNAJB1::PRKACA involving the catalytic subunit of protein kinase A (PKA). The study also considers FLC-like tumors with additional PKA-related alterations.","Answer",{"name":130,"@type":125,"acceptedAnswer":131},"How was the multi-omics analysis performed?",{"text":132,"@type":128},"RNA-seq data from 1412 liver tumors spanning FLC, hepatocellular carcinoma, hepatoblastoma, and intrahepatic cholangiocarcinoma were analyzed, with further integration using multi-omics and single-cell spatial transcriptomics on a spatially resolved characterization of FLC.",{"name":134,"@type":125,"acceptedAnswer":135},"What do the transcriptomic signature results show about FLC and FLC-like tumors?",{"text":136,"@type":128},"The transcriptomic FLC signature identifies a unifying phenotype across FLC tumors regardless of how PKA was activated, showing that FLC and FLC-like tumors behave as a single disease with a common transcriptome rather than distinct diseases with similar pathology.","https://schema.org",{"og:url":99,"og:type":139,"og:title":65,"og:site_name":110,"og:description":66},"article",{"robots":141,"canonical":99},"index,follow",{"doc_id":61,"site_id":74},1790193420]